Chronic myelogenous leukemia (CML) is caused by expression of the BCR-ABL tyrosine
kinase oncogene, the product of the t (9; 22) Philadelphia translocation. Patients with CML in …

The degree of tumor load reduction after therapy is an important prognostic factor for
patients with CML. Conventional metaphase analysis has been considered to be the 'gold …

Allogeneic stem cell transplantation (SCT) plays a central role in chronic myeloid leukemia
(CML) because it remains the only treatment with proven curative potential. For this reason …

We assessed long-term outcome in 155 patients who had undergone an
allogeneic/syngeneic stem cell transplant (SCT) and were in complete remission for more …

The impact of allelic HLA matching in patients with AML and myelodysplastic syndrome
(MDS) who receive allogeneic PBSC after a reduced-intensity conditioning (RIC) regimen is …

Introduction. The survival of patients with chronic myelocytic leukemia (CML) has improved
during the past decades. However, there have been discrepancies between results reported …

The purpose of this prospective cohort study was to identify pretransplant and transplant
predictors of 1-year survival after allogeneic hematopoietic stem cell transplantation (HSCT) …

BACKGROUND The relationships between psychological and behavioral variables and
patient outcomes after hematopoietic stem cell transplantation (HSCT) are not known …

Chronic myeloid leukemia (CML) is a stem cell disease characterized by excessive
accumulation of clonal myeloid (precursor) cells in hematopoietic tissues. CML cells display …

We analysed 86 patients with CML who received unrelated cord blood transplantation
(UCBT), identified through a registry of the Japan Cord Blood Bank Network. At …